Ohnishi K, Nomura F, Ito S, Fujiwara K
Third Department of Medicine, Saitama Medical School, Japan.
Hepatology. 1996 May;23(5):994-1002. doi: 10.1053/jhep.1996.v23.pm0008621181.
To assess the efficacy of ultrasound (US)-guided percutaneous acetic acid (in concentrations of 15%, 20%, 30%, 40%, and 50%) injection for small hepatocellular carcinomas (HCCs) for long-term prognosis, percutaneous acetic acid injection using 15% to 50% acetic acid was performed in 91 patients with one to four HCCs smaller than 3 cm during the past 6.5 years. During the series of treatment sessions for each patient, the same concentration of acetic acid was used. All tumors could be treated successfully with percutaneous acetic acid injection despite the differences in acetic acid concentration used. The number of treatment sessions to treat similar size of tumor was less when the higher concentration of acetic acid was used. No serious complications occurred as a direct sequela to percutaneous acetic acid injection. None of the tumor treated regrew. The 1-, 2-, 3-, 4-, and 5-year survival rates for 91 patients were 95%, 87%, 80%, 63%, and 49%, respectively. The 1-, 2-, 3-, 4-, and 5-year cancer-free survival rates of these patients were 83%, 54%, 50%, 37%, and 29%, respectively. Both liver function and size of tumor affected both survival rate and cancer-free survival rate significantly, but the number of tumors did not. The concentration of acetic acid did not affect the survival rate. Percutaneous acetic acid using 15% to 50% acetic acid will be effective therapy for small HCCs for long-term prognosis.
为评估超声（US）引导下经皮注射不同浓度（15%、20%、30%、40%和50%）乙酸对小肝细胞癌（HCC）长期预后的疗效，在过去6.5年中，对91例有1至4个直径小于3 cm HCC的患者进行了经皮注射15%至50%乙酸的治疗。在每位患者的一系列治疗过程中，使用的乙酸浓度相同。尽管使用的乙酸浓度不同，但所有肿瘤均能通过经皮乙酸注射成功治疗。使用较高浓度乙酸时，治疗相似大小肿瘤所需的治疗次数较少。经皮乙酸注射未直接导致严重并发症。所有治疗的肿瘤均未复发。91例患者的1年、2年、3年、4年和5年生存率分别为95%、87%、80%、63%和49%。这些患者的1年、2年、3年、4年和5年无癌生存率分别为83%、54%、50%、37%和29%。肝功能和肿瘤大小均对生存率和无癌生存率有显著影响，但肿瘤数量没有影响。乙酸浓度不影响生存率。经皮注射15%至50%乙酸对小HCC的长期预后将是一种有效的治疗方法。
